Cefuroxime AxetilAL-CEFUROXIME
Recommended Infectious diseaseUnrestrictedNot applicable line
Treatment of mild to moderately severe infections caused by sensitive bacteria, including tonsillitis, pharyngitis, and acute bacterial otitis media.
1
Submissions
2015–15
On the record
—
ICER range
Not modelled
Cost basis
Decision on record
- Meeting Mar 2009 Recommended Antibiotic no PSD
Access path
- TGA registered · AL-CEFUROXIME
TGA label narrower than the PBS population
- Nov 2015Recommended
- PBS listing · Unrestricted
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
4.1 The PBAC recommended the listing of a new pack size of 20 for the currently listed pharmaceutical item cefuroxime, tablet 250 mg (as axetil).PSD · Nov 2015
4.2 The PBAC recommended the listing of a new pharmaceutical item cefuroxime, powder for oral suspension 125 mg (as axetil) per 5 mL, 100 mL.PSD · Nov 2015
Cost-effectiveness
Not modelled; minor submission (formulation and pack size change only).
The PBAC noted a small net cost to the PBS as a consequence of the reduction in repeat scripts which patients will no longer require because of the larger presentation for both tablets and suspension. PBAC · 2015
Cost-effectiveness accepted
Decision context
PopulationPatients requiring treatment for mild to moderately severe infections caused by sensitive bacteria; specific subgroup consideration for paediatric patients 3 months to 12 years of age for the suspension formulation.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2015 | Recommended | — | — | Cost-minimisation · Cost-minimisation |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to mild-to-moderately severe infections caused by sensitive bacteria; TGA label includes bronchitis and other infections without severity or sensitivity qualifiers.